RecruitingNot ApplicableNCT06094608
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
Sponsor
University of Michigan
Enrollment
68 participants
Start Date
Feb 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This research study is testing whether changes in sleep timing and morning light treatment may have an impact on symptoms related to inflammatory bowel disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Biopsy-proven IBD
- Active IBD symptoms
- Impaired IBD quality of life
- Age \>/=18 years old
- Fluency in English
- Physically able to travel for study visits
Exclusion Criteria11
- Ileostomy, colostomy, ileoanal pouch, or ileorectal anastomoses, are planned for imminent surgery and/or have short bowel syndrome
- Other significant chronic disease
- Retinal pathology, history of eye surgery, taking photosensitizing medications
- Recent history of light treatment
- Lifetime psychotic or bipolar disorder
- Acute suicidal ideation
- Substance use disorder in the past 3 months, cannabis use \>1/week
- High risk for or diagnosed with obstructive sleep apnea, and/or narcolepsy
- Severe hearing problem, intellectual disability or serious cognitive impairment
- Pregnant, trying to get pregnant, or breastfeeding
- Night work or travel outside the eastern time zone in the past month
Interventions
DEVICEMorning light treatment
Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
BEHAVIORALTreatment-as-usual
Participants will not make modifications to their activities or sleep schedule.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06094608
Related Trials
Combined Immunosuppression for Pediatric Crohn's Disease
NCT050438701 location
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT0609512849 locations